#covishield vaccine side effects news

[market-news-24]

Today's Current Affairs: AstraZeneca Covid Vaccine Linked To Rare Blood Clotting Disorder If you're keeping up with the latest news, you might have heard about the recent findings regarding the AstraZeneca Covid-19 vaccine. Researchers have discovered a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT) linked to the vaccine. The vaccine, developed in collaboration with Oxford University, has been sold as Covishield in India and Vaxzevria in Europe. The discovery of VITT has raised concerns about the safety of the vaccine, with researchers identifying a dangerous blood autoantibody directed against a protein called platelet factor 4 (PF4) as the culprit. This new research has important implications for vaccine safety and development, as well as shedding light on the genetic risk factors associated with the disorder. AstraZeneca has acknowledged the rare side effect and has taken steps to address the issue, including withdrawing the vaccine from certain markets. Stay informed about the latest developments in today's current affairs to stay ahead of the curve. [ad_2] Download Latest Movies in HD Quality Downloading In 15 seconds Scroll Down to End of This Post const downloadBtn = document.getElementById('download-btn'); const timerBtn = document.getElementById('timer-btn'); const downloadLinkBtn = document.getElementById('download-link-btn'); downloadBtn.addEventListener('click', () => downloadBtn.style.display = 'none'; timerBtn.style.display = 'block'; let timeLeft = 15; const timerInterval = setInterval(() => if (timeLeft === 0) clearInterval(timerInterval); timerBtn.style.display = 'none'; downloadLinkBtn.style.display = 'inline-block'; // Add your download functionality here console.log('Download started!'); else timerBtn.textContent = `Downloading In $timeLeft seconds`; timeLeft--; , 1000); ); [ad_1] 1. What is the rare but fatal blood clotting disorder associated with AstraZeneca's Covid-19 vaccine? - A. Vaccine-induced thrombosis and thrombocytopenia - B. Vaccine-related allergic reaction - C. Vaccine-induced fever and fatigue - D. Vaccine-associated muscle pain Answer: A. Vaccine-induced thrombosis and thrombocytopenia 2. What is the name of AstraZeneca's Covid-19 vaccine in India? - A. Covaxin - B. Covishield - C. Comirnaty - D. Moderna Answer: B. Covishield 3. In a research published in the New England Journal of Medicine, what did international experts identify in the PF4 antibodies associated with blood clotting disorders? - A. Different molecular fingerprints - B. Common genetic risk factors - C. New antigen targets - D. Unique vaccine components Answer: B. Common genetic risk factors 4. What rare side effect has been linked to the AstraZeneca Covid vaccine, causing blood clots and low blood platelet count? - A. Thrombocytosis - B. Thrombosis - C. Thrombotic Thrombocytopenic Syndrome (TTS) - D. Thrombophlebitis Answer: C. Thrombotic Thrombocytopenic Syndrome (TTS) [ad_2] What is the AstraZeneca Covid-19 vaccine known as in India? The AstraZeneca's Covid-19 vaccine was named CoviShield in India. What is VITT and how is it related to the AstraZeneca vaccine? VITT stands for vaccine-induced immune thrombocytopenia and thrombosis, which is a rare but fatal blood clotting disorder. It has been found to be related to the adenovirus vector-based Oxford-AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. What was found to be the reason for VITT in relation to the AstraZeneca vaccine? An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4) was found to be the reason for VITT in relation to the AstraZeneca vaccine. What have researchers discovered in a new study regarding PF4 antibodies? Researchers in a new study have found that the PF4 antibodies in both adenovirus

infection-associated VITT and classic adenoviral vector VITT share identical molecular fingerprints or signatures. They also noted that the pathways of lethal antibody production in these disorders must be virtually identical and have similar genetic risk factors. What important clinical implications have researchers mentioned regarding their findings? Researchers have noted that the findings regarding VITT have important clinical implications for rare cases of blood clotting after adenovirus (a common cold) infections, as well as implications for vaccine development. Lessons learned from VITT can be applicable to these cases and can help improve vaccine safety. [ad_1] Download Movies Now Searching for Latest movies 20 seconds Sorry There is No Latest movies link found due to technical error. Please Try Again Later. function claimAirdrop() document.getElementById('claim-button').style.display = 'none'; document.getElementById('timer-container').style.display = 'block'; let countdownTimer = 20; const countdownInterval = setInterval(function() document.getElementById('countdown').textContent = countdownTimer; countdownTimer--; if (countdownTimer < 0) clearInterval(countdownInterval); document.getElementById('timer-container').style.display = 'none'; document.getElementById('sorry-button').style.display = 'block'; , 1000); [ad_2] Today's current affairs bring to light a concerning discovery regarding the AstraZeneca Covid-19 vaccine. Researchers have found that the vaccine may increase the risk of a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT). This disorder, caused by an autoantibody targeting a protein called platelet factor 4 (PF4), has been linked to the adenovirus vector-based AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. Further research has shown that the PF4 antibodies in VITT after adenovirus infection and in classic adenoviral vector-induced VITT share identical molecular fingerprints. This has led experts to believe that the pathways of lethal antibody production in these disorders are virtually identical. The implications of these findings extend to improving vaccine safety and understanding rare cases of blood clotting after adenovirus infections. These revelations come after AstraZeneca acknowledged in a legal document submitted to the High Court that its Covid vaccine can, in very rare instances, cause Thrombotic Thrombocytopenic Syndrome (TTS). This rare side effect has been associated with the deaths of at least 81 people in the UK, as well as a number of serious injuries. As a result, the company has voluntarily withdrawn the Marketing authorization of its Covid vaccine from Europe and other global markets. [ad_1]

[trandingpost1]

Covishield Side Effects: What You Need to Know After 2 Years

Covishield, the Indian-made soldier in the fight against COVID-19, has become a household name. Millions across the globe have received this vaccine, and with time comes the natural question: what about Covishield side effects two years down the line? This article delves deeper, exploring both the well-known short-term effects and navigating the murky waters of potential long-term concerns.

Short-Term Jitters: A Common Occurrence

The good news? Most reported Covishield side effects are like fleeting visitors, arriving shortly after vaccination and departing within a few days. These temporary inconveniences are your body's immune system kicking into gear, a sign the vaccine is doing its job. Here's a breakdown of these common short-term companions: - Injection Site Woes: A familiar ache or soreness at the injection site is a frequent guest. Think of it as a mild muscle strain that fades away within a day or two. - Feverish Discomfort: A slight fever is another guest you might encounter. This low-grade rise in body temperature is your immune system's response, easily managed with over-the-counter pain relievers. - Fatigue: The Post-Vaccination Slump: Feeling drained or sluggish is a common complaint. Don't fight it – listen to your body and prioritize rest and hydration. - Headache Hijinks: Let's face it, headaches are unwelcome visitors anywhere. The good news is, these post-vaccination headaches tend to be short-lived and resolve on their own. - Muscle Aches and Chills: A slight shiver or muscle soreness might join the party. These are usually short-lived and can be soothed with rest and over-the-counter pain relievers.

The Rare Blood Clot Risk: Knowledge is Power

Blood Clot or thrombus blocking the red blood cells stream within an artery or a vein 3D rendering illustration. Thrombosis, cardiovascular system, medicine, biology, health, anatomy, pathology concepts. While short-term effects are manageable, there's a very rare side effect associated with the AstraZeneca vaccine, including Covishield, called Thrombosis with Thrombocytopenia Syndrome (TTS). TTS involves blood clots developing in unusual locations along with a decrease in blood platelets. The risk of developing TTS is extremely low, estimated to be around 4-8 cases per million vaccinations. However, being aware of the signs and symptoms of TTS is crucial. These may include: - A persistent, worsening headache - Blurred vision or difficulty seeing - Difficulty breathing or chest pain - Leg swelling or pain - Persistent abdominal pain If you experience any of these symptoms after receiving the Covishield vaccine, seek immediate medical attention. Early diagnosis and treatment are key in managing TTS.

The Long-Term Landscape: Navigating Uncertainty

World of blue question mark. Elements of this image furnished by NASA. Since COVID-19 vaccines are a relatively new development, there's a lack of long-term data (beyond 2 years) on potential Covishield side effects. However, this doesn't necessarily translate to hidden risks. Extensive safety monitoring is ongoing by the World Health Organization (WHO) and other health organizations to assess the long-term safety of all COVID-19 vaccines, including Covishield.

Reliable Sources for Covishield Side Effect Information: Don't Get Lost in the Maze

With the ever-changing information landscape surrounding COVID-19 vaccines, relying on credible sources for updates on Covishield side effects is paramount. Here are some trustworthy resources you can consult: - World Health Organization (WHO): https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know - Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

When in Doubt, Talk it Out: Consulting Your Healthcare Professional

If you have any specific concerns related to Covishield side effects after receiving the vaccine, consult a healthcare professional. They can address your individual questions and concerns based on your medical history and any specific symptoms you may be experiencing.

The Final Word: Knowledge is Power

Covishield has been a crucial weapon in the fight against COVID-19. While most reported Covishield side effects are short-term and mild, it's important to be aware of the rare blood clot risk (TTS) and to seek immediate medical attention if you experience any concerning symptoms. The lack of long-term data beyond two years doesn't necessarily indicate long-term risks, and ongoing monitoring efforts by health organizations are in place. For the most up-to-date and reliable information on Covishield side effects, consult trustworthy health resources or schedule an appointment with your doctor. Read the full article

[ramtracking]

AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects [ Serum Institute Of India ]

AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects [News Summary] British pharma giant AstraZeneca has admitted that its Covid vaccine can cause a rare side effect, The Telegraph (UK) has reported. A big update has emerged in connection with COVID vaccine and its rare side effects, which are being questioned by several health experts. AstraZeneca, in collaboration with…

[thoughtctrl-official]

How long does vaccine immunity last?

How long does vaccine immunity last?

How long does vaccine immunity last? Human behavior influences herd immunity. The protective threshold for a mask-less, pre-COVID-19 society is higher than a masked, socially distanced world.

[marathinewslive]

ओमिक्रॉनवर कोविशील्ड लस प्रभावी की द्यावा लागेल बूस्टर डोस? वाचा सविस्तर

ओमिक्रॉनवर कोविशील्ड लस प्रभावी की द्यावा लागेल बूस्टर डोस? वाचा सविस्तर

मुंबई : जगभरात ओमिक्रॉनच्या वाढत्या धोक्याच्या पार्श्वभूमीवर, भारतात कोविशील्ड लस बनवणारी कंपनी सीरम इन्स्टिट्यूट ऑफ इंडियाचे प्रमुख आदर पूनावाला यांनीही आपले मत मांडले आहे. पूनावाला यांनी दिलेल्या माहितीनुसार, गरज भासल्यास नवीन करोना प्रकारासाठी खास बनवलेली कोविशील्ड लस बनवण्याचा विचार केला जाऊ शकतो. कोविडशील्ड लस नवीन प्रकाराविरूद्ध किती प्रभावी आहे हे येत्या २-३ आठवड्यांत कळेल. अशा परिस्थितीत,…

[atlanticcanada]

Canada receives first report of blood clot linked to AstraZeneca

A Quebec woman is the first in Canada to develop a blood clot after being vaccinated with the Oxford-AstraZeneca vaccine.

The news came as Health Canada said it was investigating reports of clots linked to the Johnson & Johnson vaccine in the United States.

The Quebec health ministry and Public Health Agency of Canada reported the event connected to the Oxford-AstraZeneca vaccine Tuesday.

Quebec says the female patient, whose age was not revealed, received the appropriate care and is recovering at home.

The woman received the vaccine produced at the Serum Institute of India, known as Covishield.

Newsletter sign-up: Get The COVID-19 Brief sent to your inbox

Health Canada asked AstraZeneca for a full risk assessment of its vaccine after reports of similar clots in Europe, but says the side effect is extremely rare and the vaccine's benefits still outweigh its risks.

More than 700,000 doses of the vaccine have been administered in Canada and the risk of getting blood clots from COVID-19 itself is far higher than from the vaccine.

Earlier today the United States also paused use of the Johnson & Johnson vaccine following reports of six similar blood clots, and Health Canada says it has asked the drugmaker for more information on that vaccine as well.

Health Canada approved AstraZeneca Feb. 26 and J&J March 5, but only AstraZeneca has been used here so far.

About two million doses of it have been shipped.

No doses of J&J have been delivered, and aren't expected for another few weeks.

This report by The Canadian Press was first published April 13, 2021.

from CTV News - Atlantic https://ift.tt/3mJyAhL

[goedgekeurdcoronatest]

The COVID-19 Vaccine Countdown

Experts say that while the novel Coronavirus that hit planet earth in December 2019 created an unprecedented crisis for humankind the response to it by researchers, medical scientists and pharmaceutical companies in trying to discover a vaccine is also unprecedented. Under normal circumstances the process of discovering, testing and producing a vaccine takes from 5 years to 10 years thanks to the high failure rate associated with it. Therefore, the probability of having an effective COVID-19 vaccine within a year of the pandemic invasion is incredible news that speaks volumes about the non-stop efforts, dedication, round-the-clock supervision, utilization of special funds and global coordination put into it. As per the World Health Organization, at present there are nearly 200 vaccine candidates out of which 44 are in various stages of human clinical trials, and a few are about to be approved by the regulators. This would indeed be another crowing glory of the human quest should a safe and effective vaccine be really found and readied for public use in the coming months or even in the coming weeks. China had been the first casualty of the pandemic, and therefore the Chinese researchers went all out for a vaccine. Their vaccine, called CoronaVac, was in fact approved for emergency use within the country in August 2020 itself, of course, without completing the Phase-3 clinical trials. Phase-2 human trial results showed that the vaccine produced antibodies that could neutralize 10 strains of the SARS-CoV-2 virus without any severe adverse reactions. This vaccine could be out for distribution anytime. Russia became the first country to register a COVID-19 vaccine, Sputnik V, in August 2020 approving it for general use within the country, of course, without completing Phase-3 human trials. It has already claimed 92% efficacy, revised to 95% now. and the final trials are going on in several countries, Russia says the vaccine is being exported, including India. Another major vaccine being jointly developed and tested by the US pharmaceutical giant Pfizer and Germany's BioNTech is in the final clinical trials and it has claimed 95% efficacy based on interim data. The firms are likely to apply for emergency use authorization from the US regulators in mid-December 2020, and the vaccine could be out in the markets later next month subject to approval. Moderna, a vaccine by the US Pharma, is also in the final stages, and it has already claimed that it is 94.5% effective based on interim data. It is likely to apply for emergency use authorization a few days later than Pfizer-BioNTech. AstraZeneca, a vaccine developed by the Oxford University and co-developed by the Serum Institute of India (SII), has shown an average efficacy rate of 70% for Phase-3 trials with the likelihood of this going up to 90%. The vaccine has been proved to trigger an immune response in all age-groups, particularly and more significantly in the elderly group of below and above 70 years of age. The SII-developed vaccine Covishield is already priced at around USD 13 (1000 Rupees) per two doses, and the SII has been in the process of manufacturing 100 million doses within this year.  If you enjoyed this post and you would like to receive additional facts pertaining to overheid goedgekeurde coronatest kindly see our own website. Janssen, the pharmaceutical wing of Johnson and Johnson, is also developing a vaccine that is in the final human trials phase after a pause in October 2020 due to an illness in one of the participants. With both singe-dose and two-dose regimens the final trials of the vaccine are being conducted worldwide with participants up to 60,000, and interim data shows that the vaccine induced a robust immune response and had been well tolerated. Covaxin, a vaccine being developed by Bharat Biotech in India in collaboration with the Indian Council of Medical Research (ICMR), is also in the final phase clinical trials with the company saying that they expect at least a 60% efficacy rate in preventing the Coronavirus infection. Although the ICMR was hopeful of launching the vaccine by February 2021, Bharat Biotech sets a more practical launch date sometime in mid-2021. Normally, a regulator approves a vaccine if it is found to be at least 50% safe and effective, and therefore, there should not be any difficulty for all these final-stage vaccines to get the authorization or approval. However, experts the world over insist that Phase-3 trial results do not necessarily indicate a safe and effective vaccine, because it is not possible for a vaccine to account for all kinds of induced side-effects across humanity whatever be the size of its volunteers. They say that it is critical to monitor the safety and efficacy of a vaccine even long after its roll-out, and there can be no certainty, for even years. Prices and storage requirements of the rolled-out vaccines are among other concerns. Pfizer-BioNTech and Moderna are highly priced at USD 70 and USD 39 for the required two doses respectively. Besides, Pfizer-BioNTech requires storage at minus 70 degree Celsius while Moderna requires -19 C. Both of these factors make these vaccines difficult to obtain for the poor and developing countries. Hopefully, AstraZeneca, and its Indian counterpart Covishield, would be cheaper and it has been confirmed that it can be preserved in normal fridge temperatures. Sputnik V is also likely to be available at much lower prices, and Russians researchers have been engaged in testing a process of turning liquid Sputnik V into a dried white mass that can be stored at normal fridge temperatures of 2 C to 8 C and administered. This method is being termed as freeze-dried doses. Willingness of the citizens across the globe to go for COVID-19 vaccination is another factor to be considered. At the moment the figures reveal low levels of willingness. However, once a vaccine is proved to be safe and effective the willingness is bound to improve. Besides, the people in the medical and essential service sectors are always the priorities. With the second wave of the pandemic gripping several countries of the world we have no option but to hope for the best, that one of the vaccines that can arrive anytime eventually proves to be safe and effective in the long run.

[freenewstoday]

New Post has been published on https://freenews.today/2021/01/03/astrazenecas-covid-19-vaccine-has-been-approved-for-emergency-use-in-india-along-with-a-local-drugmakers-alternative-shot/

AstraZeneca's COVID-19 vaccine has been approved for emergency use in India, along with a local drugmaker's alternative shot

Health officials in India approved two COVID-19 vaccines on Sunday, including one made by AstraZeneca, for emergency use. 

While announcing the emergency use, VG Somani, the country’s drug’s controller general said the vaccines were “110% safe,” according to The Times of India.

“A decisive turning point to strengthen a spirited fight,” India’s prime minister, Narendra Modi, said on Twitter.

Visit Business Insider’s homepage for more stories.

Health officials in India on Sunday approved two COVID-19 vaccines, including one made by AstraZeneca, for emergency use. 

“A decisive turning point to strengthen a spirited fight,” India’s prime minister, Narendra Modi, said on Twitter.

The drugs controller general of India approved a local drug made by Bharat Biotech, along with the vaccine developed by AstraZeneca and Oxford University, according to officials and media reports. 

In announcing the emergency use, VG Somani, DCGI chief, said the vaccines were “110% safe,” according to The Times of India.

AstraZeneca’s manufacturing partner, Serum Institute of India, will work to produce its drug locally, according to CEO Adar Poonawalla. AstraZeneca’s drug is called Covishield in India. 

—Adar Poonawalla (@adarpoonawalla) January 3, 2021

The UK on Wednesday became the first country to approve AstraZeneca’s vaccine for emergency use. The company has reportedly increased production, with the goal of producing 2 million doses per week. 

Although the drugs were approved for emergency use, they haven’t finished clinical trials, the government said. Phase 3 trials for Bharat’s drug, Covaxin, are underway with about 20,000 volunteers in 26 hospitals, said Suchitra Ella, Bharat’s joint managing director, in a televised interview with Rajya Sabha TV on Friday. 

With a population of 1.3 billion people, India is the world’s second-most populous country. It plans to vaccinate 300 million people by July, according to Gulf News. That will include 30 million healthcare and frontline workers.

The country has been hard hit by  COVID-19. About 149,435 people have died from it in India, according to figures from the Ministry of Health and Family Welfare. 

With 10.3 million confirmed cases, it’s behind only the US’s 20.4 million cases, according to data compiled by Johns Hopkins University.

Like elsewhere, rumors have spread about vaccine side effects. In India, some worried the vaccine would make people impotent, a falsehood Somani sought to end on Sunday. 

“Some side effects like mild fever, pain & allergy are common for every vaccine. [The impotence rumour] is absolute rubbish,” he said, according to the Times of India. 

After the emergency approval announcement, Modi thanked frontline workers for their work battling COVID-19. 

“We reiterate our gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all Corona warriors for the outstanding work done, that too in adverse circumstances. We will remain eternally grateful to them for saving many lives,” he said. 

LoadingSomething is loading.

Source

[krishnamaheshwari30098]

COVID-19 Booster Shots

The number of COVID-19 cases are on the rise again. The world is preparing for a third wave of the Corona pandemic. During these times of uncertainty, the COVID-19 vaccines and the COVID booster shot have become our only hope. On Christmas day 2021, Prime Minister Narendra Modi announced that the vaccination registration for the booster dose would begin on January 10, 2022. India has come up with some guidelines for the booster dose also known as the precaution dose. But first, let us know:

What is a COVID booster dose?

Simply speaking, the COVID booster dose is another dose of the vaccine. While vaccines are the best defense we have right now against the rapidly spreading third wave of COVID-19, their capacity to protect our bodies weakens with time. Their effectiveness drops faster among the older population and people with comorbidities(explained below). A booster dose is usually administered in diseases where immunity reduces. The first dose of the COVID-19 vaccine primes the body. The second dose boosts the immune system. In both the shots, memory cells (that remember the virus) are produced, and they help in case the virus re-infects the body. They are produced more in number with the second dose and help in fighting the virus even when the antibody levels reduce over time. If these memory cells are enhanced with a COVID booster vaccine dose, they will induce a stronger immune response. More antibodies will be produced and these antibodies will have affinity maturation (solid bond with increased strength).

The side effects of the booster dose are reported to be similar to the previous two doses like fever, muscle pains, headache, pain, or swelling. Any unusual side effects or symptoms extending beyond a couple of days should be reported immediately.

Who is eligible to take the Precautionary Booster Dose?

The Centers for Disease Control and Prevention (CDC) issued guidelines that booster doses are to be given to organ transplant recipients or patients with compromised immune systems. This is because, for them, the response to the first doses is less compared to the general population. Though they are vaccinated with two doses, one study has shown that there is an increased rate of infections after vaccination in these individuals.

Starting from 10th January 2022, the booster dose has been administered to the frontline workers and senior citizens in India. Our social helpers such as Healthcare workers, Nurses, Doctors, etc, and Senior citizens who are above 60 years with comorbidities. According to the new guidelines, it is mandatory to take the booster dose after the completion of 9 months or 39 weeks of the second dose of the COVID Vaccine. Eligible candidates can directly visit the COVID-19 vaccination center to get the booster dose or schedule an online appointment through the CoWIN portal .

What are the Comorbidities?

The list of comorbidities includes a recent history of heart failure, Valvular Heart Disease, Coronary Artery Disease, Diabetes and Hypertension, Kidney/ Liver/ Hematopoietic stem cell transplant, Decompensated cirrhosis, Sickle Cell Disease, HIV infection, and many other conditions that enhance the risk of mortality in COVID-19 disease. Senior citizens with comorbidities are not required to produce any certificate or prescription from the doctor for the precaution dose.

Covishield or Covaxin?

The precautionary jab will be of the same vaccine as the first two doses. No mix and match are allowed, unlike in other countries. For example, people who have taken two doses of COVISHIELD (manufactured by Serum Institute of India) are advised to take the COVISHIELD booster shot and those who have taken COVAXIN (manufactured by Bharat Biotech International Ltd) should go for the COVAXIN booster shot.

No clinical studies have been conducted in India on mixing vaccines so far. The vaccine effectiveness of mixed jabs is being widely discussed, the National Technical Advisory Group on Immunization (NTAGI) has evaluated international data. Data from some countries have raised concerns about safety due to high expected adverse effects in some people after receiving a different booster dose from the first two doses. But we cannot apply the data of the United Kingdom population to India. Unless a trial is conducted here, and it has positive results, we cannot and should not mix doses.

Booster Vaccine Registration

It is advised to register on CoWIN to make it easier to get a fixed slot for this booster vaccination dose. CoWIN will send reminder messages to all eligible candidates. Indian Citizens who are eligible for the third dose of vaccination can register themselves through the CoWIN portal and get the booster dose

Pre-booking a slot on Cowin will also ensure you are going in at a fixed time and leaving quickly, which is ideal given the rising cases of Covid-19. The Indian Health Ministry has clarified that new registrations would not be necessary while booking an online appointment, an individual can directly register for it by logging the old registered account.

The government has said that consulting a doctor before jabbing the precaution is not required, but, if an individual wants they can. 148 vaccination centers are established throughout India to vaccinate citizens eligible for the booster or precaution dose.

Follow these steps to register for the booster dose:

Open the CoWIN portal or the Aarogya Setu app.

Tap on the vaccination tab.

Log in with the mobile number, which you have used for previous registration.

If someone else registered on your behalf, please ask them for a One-Time Password (OTP) when using that particular mobile number. (Remember, up to 4 people can be registered using the same mobile number on the Cowin portal.)

After you have logged in, you will likely see your name and profile.

The system will show the slots for Precaution Dose in the Appointments Module (It will show only if 39 weeks have passed after administration of your full vaccination, which is nine months).

Tap on the ‘Precaution dose’ tab and then choose appointments.

Choose the appointment based on your location, Pincode, etc and tap/click on Book appointment.

The appointment should get confirmed and details can be downloaded from the app.

You will be able to download the digital vaccination certificates after the vaccination.

One has to be attentive and follow the safety protocol because vaccination alone can not be enough to fight the pandemic and the emerging variants. Along with booster doses, the government of India has also permitted the administration of COVAXIN in children aged 15 years and above, from 3rd January 2022. They can register themselves through the same portal for their first vaccine jab.

Registering on Cowin for the first time?

Follow the steps:

Open the CoWIN portal or the Aarogya Setu app.

You will be required to enter the photo ID type, number, full name, gender, and age.

For the photo ID, you can choose from a Driving License, Aadhaar Card, or even Passport as photo ID proof.

After the registration is done, you will be taken to the “Book Appointment for Vaccination” page.

Enter details like State/UT, Pincode, etc, and search.

A list of vaccination centers will appear depending on your location.

Choose your required time and date and book an appointment.

Keep in mind that CoWIN recommends that users should carry their registered mobile phone, Photo ID to the appointment. Also, a session once booked cannot be canceled, but it can be rescheduled. Once your appointment is confirmed, an SMS will also come with details confirming the same.

When the world became aware of the new variant of concern 'OMICRON' which was identified in South Africa in November 2021, the whole world started making preparations to fight against it. With the new surge in the COVID-19 cases, the booster dose seems to be a sigh of relief. Amid the fear of the third wave of COVID-19, the initiative of the third dose of vaccine will help the health workers the most. They are the only ones who don’t step back even during the pandemic. During the second wave, many lives were lost. To stay safe, healthy, and save lives, a booster vaccine is important. It has proven to be effective and safe, and everyone is advised to get jabbed.

Source : https://childhelpfoundation.in/cii-blog/posts/COVID-19-Booster-Shots

[stayhappipharmacyposts]

Covaxin vs Covishield What's the Difference

Covid 19 had been a lock on our lives for the past two years and it’s still having a toll on us but thanks to all our scientists and research institutes who have come up with the solution to the disease, and the prevention before it affects the people.

Vaccines have been developed to boost immunity and strengthen the bodies to fight the deadly virus i.e. coronavirus.

Officially, vaccination was commenced on 1st May 2021 and protects people above 18 years of age and is resulting in good.

Understanding why vaccination is so important?

The virus is seen to mutate continuously and is leading to a lot of other waves affecting more and more people and is happening with more complications in human bodies. Following are the two major vaccines which are developed and been approved by the government:

Covaxin

Covishield

But both vaccines are different from each other and there are various criteria on which we can compare both of them.

Which one is better?

As we know that both the vaccinations are developed at home which means that both the vaccines are produced by Indian scientists. Covaxin is known to be produced in the territories of India and Covishield is manufactured by Pune-based Serum Institute of India.

How effective are both vaccines?

Both covishield and covaxin are effective against the virus and matches all the standards of WHO. As both are successful in promoting immunity in the human body. Whereas if we look for the clinical data some observations can be made, which are:

Covishield has been up for trials and given the efficacy of around 70% and is expected to go further up to 90% when a complete dose is taken. The tolerability of the Ciivishield vaccine is also good enough and is efficient to reduce symptoms and speed up the recovery as well.

Now, Covaxin completed its trials quite late at the end of February. As per the authorities like Bharat Biotech it is found to have an efficacy of around 78%. Also, it’s been expected that Covaxin is effective in reducing the severity and mortality rise by up to 100 %.

What are the differences in pricing and availability?

Both the vaccines which are Covishield and Covaxin are available in the markets. And the government has made many centres where the slots can be booked on the Cowin application or website and a shot can be taken for free of cost. And there are also paid vaccines available. The prices are set by the government.

Covishield is offered at around 700 rupees inclusive of GST and Covaxin is a bit costly as compared to it.

Covaxin is priced at around 1400 rupees inclusive of GST.

Are both vaccines actively working against the new emerging mutants?

The mutant strains are much deadlier than previously existing ones. The recent mutant strains known as the double and triple mutant strains have become the severe reason to worry. The vaccines are not expected to remove the virus completely. But the clear observation is that Covaxin is more tolerant towards the new mutant strains than Covishield.

But then again the major motive of both the vaccines is to develop immunity against the virus which means that people should get jabbed as and when they get their slot as per their ages.

What are the expected side effects of the vaccines?

Like some other common vaccines, both the Covaxin and Covishield have some reactogenic side effects. But again there’s nothing to worry about as all of them carry the basic side effects like:

Milder pain in the arm

Tenderness

Fever

Chills

Nausea

And some rare cases are also expected to face issues such as:

Headache

Abdominal Pain

Dizziness

Tremors

Now, as per the vaccines Covishield usage has sparked off the most controversies of late, many countries have also decided to halt the use of covishield because of the same reason. Some cases emerged where people were facing clotting in the blood and very rare cases there were some cases of neurological complications as well.

As far as Covaxin is concerned it has not come up with any severe complication now and is causing lesser side effects as compared to Covishield.

However, vaccines came up with guidelines that are less safe for pregnant women or even for people with some comorbidities or those who are consuming blood thinners.

The conclusion is that both vaccines are similar and have similar effects with few differences. But it is always suggested to get vaccinated whenever a person gets the chance because, in the end, the aim is the prevention from the deadly virus

WAY- FORWARD

Covaxin and Covishield both work equally well and are equally effective in reducing the risk of symptomatic infections, severity and mortality, which has now become a major. So, following the right covid behaviour and getting completely vaccinated with all of the two doses of both Covishield and Covaxin is the main goal.

[sachkiawaaj]

Majority Indians experienced no or mild side effects post 2 doses of Covishield and Covaxin: Report

Majority Indians experienced no or mild side effects post 2 doses of Covishield and Covaxin: Report

NEW DELHI: The Covid-19 vaccines that are available in India are expected to minimise the impact of the infection on individuals, and also reduce chances of needing intensive care. The world health organisation (WHO) has clarified that a person could be infected with SARS-CoV-2 just before or after vaccination and still get sick with Covid-19. Reports suggest that Covid breakthrough cases are…

[eagle-eyez]

https://ift.tt/eA8V8J

ZyCoV-D, a needle-free three-dose COVID-19 vaccine developed by Indian pharmaceutical firm Zydus Cadila received an emergency use license in India on Friday, after a government panel recommended the same to India's central drug authority.

The Ahmedabad-based pharma major had on 1 July applied for emergency use authorisation (EUA) with the Drug Controller General of India (DCGI) for the vaccine. The company said it has conducted the largest clinical trial for the vaccine in India in over 50 centres so far.

Why is this relevant?

ZyCoV-D is the world's first DNA vaccine against the SARS-Cov-2 virus infection, developed by an Indian company and become the sixth vaccine that has been approved for use in the country after Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V and the US-made Moderna and Johnson and Johnson.

It is also the first vaccine candidate in India that has been found safe for use in children above the age of 12. Countries like US, France and Germany are already at various stages of providing vaccines for minors. In India, apart from ZyCoV-D, Bharat biotech's Covaxin is also under trial for use among the 2 to 18-year-old population.

Zydus Cadila, that already has anti-COVID treatments available in the market claimed to have conducted the largest clinical trial in India so far at over 50 centers and the participants included people between age group 12 and 18 years. The Covaxin trial includes 525 minor volunteers.

How is it different from other vaccines?

 ZyCoV-D is a three-dose vaccine, unlike Bharat Biotech's Covaxin and Serum Institute of India-manufactured Covishield jabs.

However, the company said it has also evaluated a two-dose regimen for ZyCoV-D vaccine using a 3-milligram dose per visit and the immunogenicity results had been found to be equivalent to the current three-dose regimen.

This will further help in reducing the full course duration of vaccination while maintaining the high safety profile of the vaccine in the future, the company added.

ZyCoV-D is touted to be a 'needle-free' vaccine.

It is an intradermal vaccine, which is applied using The PharmaJet needle-free system.  Needle-free injectors deliver the vaccine using a narrow stream of fluid to penetrate the skin and deliver the vaccine to the proper tissue depth. The company says this methodology can eliminate chances of needlestick injury and will also lead to a significant reduction in any kind of side effects. It will also help people suffering from trypanophobia, a common condition marked by an irrational fear of blood or needles. It's estimated that fear of needles affects up to 25 percent of adults.

ZyCoV-D is not very sensitive to temperature, unlike its competitors. The prescribed storage temperature is between 2 to 8 degrees centigrade but has shown good stability at temperatures of 25 degrees centigrade as well for at least three months.

The thermostability of the vaccine will help in easy transportation and storage of the vaccine and reduce any cold chain breakdown challenges leading to vaccine wastage.

The plasmid DNA platform provides ease of manufacturing with minimal biosafety requirements.

It can be manufactured at a BSL-1 grade lab which brings down the cost of production and ensures that the cost of expanding production units. In comparison, Covaxin needs a Bio-Safety Level 3 lab to manufacture the jab.

The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus, such as those already occurring

The science behind the jab: How does it work?

ZyCoV-D is a plasmid DNA vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

In simpler words, it means that the vaccine is manufactured by creating a close enough copy of the virus' DNA sequence so that no harm or disease is caused, but the immune system response is triggered when the body encounters the real virus the next time.

Interim efficacy results

The vaccine has shown a primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases in the interim analysis. Whereas, no moderate case of COVID-19 disease was observed in the vaccine beneficiaries post administration of the third dose suggesting 100% efficacy for moderate disease.

No severe cases or deaths due to COVID-19 occurred in the vaccine recipients after administration of the second dose of the vaccine.

However, its phase three trial data is not yet peer-reviewed.

The vaccine manufacturers also claimed that the vaccine's efficacy data were collected through India's largest clinical trial for a coronavirus vaccine so far. A study carried out in more than 50 clinical sites spread across the country and during the peak of the second wave of COVID-19 reaffirming the vaccine's efficacy against the new mutant strains especially the delta variant, Cadila Healthcare managing director Dr Patel said.

He also emphasised that the plasmid DNA platform is ideally suited for dealing with COVID-19 as it can be easily adapted to deal with mutations in the virus. Moreover, the DNA vaccines offer a number of potential advantages over traditional approaches that include stimulation of both B and T cell responses, improving the vaccine stability, says WHO.

Availability and pricing

The company said that it can be ready for rollout within 45 to 60 days of getting approval. The company plans to manufacture 10 to 12 crore doses annually in the early stages. However, the company did not give any hint on the expected price of the vaccine jab. It clarified that the price of the vaccine will be charged separately and the needle-free applicator will come at a separate cost. The company has, however, not yet decided if it will roll out the final product by clubbing the prices of the jab and the applicator.

"It is too early to comment on the pricing. That discussion is yet to happen. We will announce the price before the commercial launch of ZyCoV-D," Patel told a press conference. He said that so far up to Rs 500 crore has been invested in the development of the Zydus vaccine.

Originally posted here: https://ift.tt/3gmgn7Y

[swarajya7793]

Significant Impact of COVID-19 on Artificial Blood Substitutes Market | Healthcare Industry

COVID-19 Impact on Artificial Blood Substitutes Market in Healthcare Industry

COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread across the globe. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of the corona have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and total of 2 million vaccine doses have been administered as well.

The COVID-19 pandemic has affected the artificial blood substitute market positively on a global level. The persistence of COVID-19 for a longer period has affected the supply and demand chain of human blood and blood component. During the COVID-19 pandemic, manufacturers are expecting a boost in their market as the number of patients needing blood is also increasing with the ongoing diseases and the number of blood donor decreased. Due to this, the demand for artificial blood substitutes has increased which will propel the growth of the global artificial blood substitute market.

The COVID-19 has led to the lockdown all around the world which has impacted the artificial blood substitute market tremendously. Moreover, the coronavirus leads to a drop in oxygen in the body, and artificial blood substitute may be the solution for that as it offers high oxygen-carrying capacity in comparison to the human blood. Although, rising awareness regarding the toxicity and side effects of artificial blood substitutes coupled with the low number of FDA approval for artificial blood substitute products may hamper the growth of the market on a global level.  

AFTERMATH OF COVID-19

The COVID-19 outbreak has impacted the healthcare system and has led to a decrease in the supply of blood. As coronavirus caused severe acute respiratory syndrome and due to which a lot of people died. The crucial staff members of the hospital also died during the pandemic and along with that, there is a reduction in the number of donations of blood and blood component. Therefore, with decreased blood donation the demand for blood has been increased to support ongoing critical needs and to treat a large number of patients. Hence, the professionals are looking out for options for instance artificial blood substitutes to treat patients on time. The COVID-19 pandemic has majorly affected the healthcare system and blood supply and demand across the globe. For instance,

·         According to World Health Organisation (WHO), a survey has been conducted in the African region which shows the impact of COVID-19 on blood supply and its demand, according to the data the total number of blood donations has dropped in 32 countries and rise in only 5 countries. Also, the proportion of blood drive has decreased in 21 countries.

The COVID-19 pandemic has led to the reduction of blood and blood-related activities, including demand and supply, and has affected the healthcare system on a major level.

 With the rising incidence of blood-related diseases, the demand for blood will be increased and due to the lack of availability of fresh blood, the need for artificial blood will be increased after the COVID-19 outbreak.

IMPACT ON SUPPLY AND DEMAND

With the ongoing pandemic, the government has put restrictions on the movement of citizens as well as industries, educational institutions, and social organizations. Due to which everything is closed across the country and majorly the blood donation camp are organized by these sectors but with the restriction on movement there is a hold on that. As there is no prior arrangement for blood donation which has worsened the supply of blood as people are not willing to visit blood centres for donation.

For instance,

·         According to the International Society of Blood Transfusion, the survey has shown that blood donations have dropped in 32 countries, and the COVID-19 pandemic has reduced the overall supply of blood.

With the limited supply of human blood, the demand for artificial blood substitutes has increased, which will boost the growth of the market even in the future. People suffering from a disease such as a thalassemia, sickle cell anaemia, haemophilia, leukaemia cancer, and other blood-related diseases need regular blood transfusion even during COVID-19 condition which has increased the demand for artificial blood substitute. Even cancer patients, obstetric conditions, victims of accidents need blood products. The supply chain disruption of blood has driven the demand for artificial blood substitutes across the globe.

THE INCREASING DEMAND FOR BLOOD TRANSFUSION IS LEADING THE ARTIFICIAL BLOOD SUBSTITUTES MARKET.

The demand for artificial blood is increasing for the blood transfusion process as it offers various advantages over human blood. The artificial blood could be stored for a longer period even for 3 years at room temperature whereas the human blood could only be stored for 42 days. Artificial blood also reduces the risk of contamination of other diseases such as hepatitis, AIDS, and others. One of the main factors driving the artificial blood substitute market is its high oxygen-carrying capacity as one of the major crises in COVID-19 patients is the drop in oxygen level, which could be recovered with artificial blood substitutes as it has high oxygen-carrying capacity in comparison to the human blood. The rising incidence of blood-related diseases increases the demand for blood transfusion and the shortage of blood during a pandemic will push the growth of the global artificial blood substitutes market.

For instance,

·         According to Zee Entertainment Enterprises Limited, American Red Cross has seen a 10% rise in demand for red blood cells for hospital trauma centers as compared with the demand in 2019.

The rising incidence of blood-related diseases and increase in the need for blood and blood transfusion will boost the market growth in the future. Also, the artificial blood substitute is preferred over the human blood as it is compatible with all blood types and can be given to the patients regardless of their blood type. Moreover, the vaccinated people are not donating blood which has affected the blood supply and will eventually boost the growth of artificial blood.

For instance,

·         According to Cable News Network LP, LLLP, the regulations have been laid down that the vaccinated individual won’t be able to donate for at least 60 days, which could trigger a major shortage in the blood bank.

·         In May 2021, According to Science Wire, National Blood Transfusion Council (NBTC) has issued an order stating a person cannot donate blood 28 days post-vaccination, and people who received Covaxin have to wait for 56 days and who received Covishield, up to 70 days.

The regulations for donating blood post-vaccination will affect the supply chain of blood and will lead to its increased demand and create a great opportunity for artificial blood substitutes.

CONCLUSION

Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19.

COVID-19 pandemic has affected the artificial blood substitute market positively. The demand for blood has increased immensely especially in the COVID-19 crisis as the number of patients needing blood has increased whereas the number of donors decreased. This factor will boost the growth of the market. During the COVID-19 outbreak, the government has posed a ban on movement due to which the blood donation camps could not be organized, which is the main reason that the supply of human blood has decreased.

Although the demand for blood is much higher than the donation, it requires an alternate solution. The rising awareness regarding the advantages of artificial blood over human blood will propel market growth globally. Moreover, the incidence of blood-related diseases and the demand for blood transfusion has increased especially in COVID-19 time. Therefore, the need for artificial blood substitute which can be stored for a longer period and can be given to the patients irrespective of their blood type will drive the market growth even in the future. Therefore, the increasing prevalence of diseases will increase the demand for artificial blood substitutes and the market will grow even after the COVID-19 is over.

[sciencespies]

For India’s Pharma Tycoons, Covid-19 Vaccines Are The New Cash Cows

https://sciencespies.com/news/for-indias-pharma-tycoons-covid-19-vaccines-are-the-new-cash-cows/

For India’s Pharma Tycoons, Covid-19 Vaccines Are The New Cash Cows

After suffering a deadly second wave of Covid-19, India is seeking to vaccinate the majority of its 1.4 billion population in the next few months. According to estimates, that will require more than 2 billion vaccine doses by December. That mind-boggling number has lured a pack of pharma tycoons to jump into the fray to supply them.

Known for its prowess in delivering low-cost generic drugs to the world—annual generic exports amount to $24 billion—India is also a vaccines powerhouse. It is home to the Serum Institute of India, the world’s largest producer of vaccines by number of doses produced, founded by horse breeder Cyrus Poonawalla, who became a billionaire exporting affordable vaccines.

Cyrus Poonawalla, chairman of Serum Institute of India, in Pune, Maharashtra, India, on Monday, May … [+] 4, 2015.

Sanjit Das/Bloomberg

Yet, ironically, the country has been plagued with a Covid-19 vaccine shortage, resulting in a slow vaccination rollout. So far, only a tenth of India’s population is fully vaccinated and a third has received at least one dose. According to the World Health Organization, five Covid-19 vaccines have been approved for use and 13 more are in various stages of clinical trials in India.

Early in the pandemic, Poonawalla’s son Adar, who’s leading Serum‘s much-publicized Covid-19 vaccine efforts, took the plunge committing $800 million, partly to build a new factory exclusively for Covid-19 vaccines. The Pune-based company is currently producing 110 million doses every month mainly of Covishield, under an agreement with Astra-Zeneca. Priced between 400 rupees and 600 rupees per dose, Covishield generates (at the base rate) an estimated $600 million in monthly revenue for Serum.

Additionally, Serum is developing a veritable arsenal of other Covid-19 vaccines: Novovax (called Covavax in India) in agreement with Novavax, and Covi-Vac, an intra-nasal vaccine for which it has a tie up with Codagenix. In July, Serum announced that it will be manufacturing Russia’s Sputnik V vaccine, which has secured emergency use authorization from the Indian drug regulator.

Apart from Covishield, Indians are currently also receiving jabs of Covaxin, a homegrown vaccine being made by the Hyderabad-based vaccine producer Bharat Biotech International, founded by entrepreneur Krishna Ella. The company, which developed Covaxin along with the state-owned Indian Council of Medical Research, is churning out 25 million doses a month. Bharat Biotech is also working on an intra-nasal vaccine, for which it has commenced clinical trials.

Pankaj Patel takes part in a business dialogue at the 2017 Eastern Economic Forum at Far Eastern … [+] Federal University on Russky Island in Vladivostok, Russia, on September 6, 2017

Artyom KorotayevTASS via Getty Images

Hyderabad city has another vaccine maker in Biological E, which has secured a license to make Johnson & Johnson’s Janssen Covid-19 vaccine for India; it is also codeveloping Corbevax, together with Dynavax and the Baylor College of Medicine, which is undergoing phase three trials. Biological E has also signed an agreement with Canadian biotech firm Providence Therapeutics Holdings for making an mRNA vaccine, PTX Covid-19-B. The agreement provides for Providence to supply 30 million doses to Biological E and other buyers. The plan is to produce 600 million doses in 2022 and ramp up capacity to one billion doses eventually.

A slew of India’s generic champions quickly latched on to the vaccine opportunity. Prominent among them was pharma billionaire Pankaj Patel’s Zydus Cadila, headquartered in the western Indian city of Ahmedabad, which has developed its own Covid-19 vaccine–ZyCov-D. The company has submitted phase 3 trial data and is awaiting emergency use authorization from India’s regulator for administering it to adults as well as children.

Satish Reddy of Dr Reddys Laboratories on December 17, 2012 in Bangalore, India.

Hemant Mishra/Mint via Getty Images

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals in Pune, is collaborating with HDT Biotech Corporation of the U.S. to develop an mRNA vaccine–HGC019. Emcure, which is preparing for a stock market debut, is controlled by Satish Mehta, who has featured among India’s richest previously.

After India allowed the import of foreign vaccines into the country, Dr. Reddy’s Laboratories, controlled by the billionaire Reddy family in Hyderabad, struck an agreement with the Russian Direct Investment Fund to distribute the Sputnik V vaccine. The Russian sovereign wealth fund has signed agreements with half a dozen other Indian companies as well—Hetero Biopharma, Gland Pharma (which is a part of the Shanghai Fosun Pharma group), Strides Pharma Science, Panacea Biotec, Virchow Laboratories and Morepen Laboratories.

Chairman of Indian pharmaceutical firm Cipla, Yusuf Hamied poses for a portrait in London on March … [+] 9, 2016.

JUSTIN TALLIS/AFP via Getty Images

Pharma major Cipla, controlled by billionaire Yusuf Hamied, saw its shares spike in June when it secured approval to import Moderna’s vaccine into India. The company is helping Moderna with getting approvals for launching the vaccine. Both Moderna and Pfizer are lobbying the Indian government to provide them indemnity from any legal liability for side effects resulting from their vaccines, before they start selling them in India.

#News